[ad_1]
Original title: With the help of the CIIE, “adopt” the new corporate health brand in the Chinese market for the first time
borrowHelped enter the Expo platform and completed the first fair in China.PfizerGlobal health formed by the merger of Pultronthe company—— 晖 致 (Viatris)companyBrandPresented at the 3rd CIIE, this is Huizhi in ChinamarketIt debuted as “Worldquality“Healthy Living” as a theme, showing its commitment to Chinese patients, government and partners.
Huizhi has a diverseproductThe combination includes approximately 1,400 compounds and biologics. Currently in China, Huizhi has more than 20 world-renowned drugs, covering multiple treatment fields such as cardiovascular and cerebrovascular, mental health, urinary, pain, liver diseases and infections, orthopedics and rheumatism, allergic reactions, including those of Puqiang’s heart and brain. Vascular fieldIconic brandProducts: Lipitor and Luohuoxi have been in the China market for more than 20 years; There are also products for men’s health.Star productsViagra has also been on the market for 20 years. Mylan’s products also have a good reputation in the Chinese market, including Supifu, Ainida, Weguli, Lijialong, etc. In the field of liver diseases and infections, in addition to the products already on the market in China, Mylan has a broad product portfolio and a global product portfolio. Mylan is a world leader in the field of HIV treatment and has a variety of new AIDS drugs for sale or in development.
“Huizhi combines the iconic Puqiang brand with Mylan’s diversified product portfolio and is able to offer products in all major therapeutic areas.”PfizerPultron Globalstrategy, Business development anddealAdvanced skillvice president, Huizhi’s futureBiggest chinaPresidentNi Xiangyang presented that the Viagra Coca-Cola disintegration tablets imported from France in October this year were launched in China. The new dosage form is more convenient to take and brings good news to Chinese ED patients. In addition, in the field of rare diseases, Revanto was also approved this year. The first phosphodiesterase type 5 inhibitor approved for the treatment of pulmonary hypertension in China. “China occupies a very important position in Huizhi’s development strategy. In the future, we will continue to deepen the Chinese market and provide the most urgently needed drugs that meet the needs of Chinese patients.”
In this CIIE, Huizhi and the Chinese populationwellnessbackgroundmeetingSign upCooperation and support to the foundation to carry out the “Guardian Online-Hypertension” at the national levelInternet +Out-of-hospital management project “approved”The Internet+ “The innovative model helps patients form good blood pressure monitoring habits and encourages medical staff to monitor and guide patients outside the hospital remotely, thus increasing awareness and control of the rate of hypertension In addition, during the CIIE, Huizhi will carry out more activities with partners.Signing and launching activities for various projects, such as the China Pain Strategy Launch Event and the “Chronic Noncommunicable Disease Medical Center-Primary Health Care “, created in conjunction with the American College of Cardiology (ACC)jobsEducation Institute “, etc., look forward to working with partners to help China strengthen chronic disease management capabilities and improve grassrootsmedical serviceThe quality and availability of drugs.
(Article source: Oriental Net)
(Editor in charge: DF155)
I solemnly declare: The purpose of this information disclosed by Oriental Fortune.com is to spread more information and has nothing to do with this booth.
[ad_2]